AVTX - Avalo Therapeutics, Inc. Stock Price, Fair Value and News

15.39USD-0.61 (-3.81%)Market Closed

Market Summary

USD15.39-0.61

Market Closed

-3.81%

AVTX Stock Price

View Fullscreen

AVTX RSI Chart

AVTX Valuation

Market Cap

15.9M

Price/Earnings (Trailing)

-0.5

Price/Sales (Trailing)

8.27

EV/EBITDA

-0.29

Price/Free Cashflow

-0.52

AVTX Price/Sales (Trailing)

AVTX Profitability

EBT Margin

-1638.77%

Return on Equity

-431.87%

Return on Assets

-150.26%

Free Cashflow Yield

-192.77%

AVTX Fundamentals

AVTX Revenue

Revenue (TTM)

1.9M

Rev. Growth (Yr)

-36.27%

Rev. Growth (Qtr)

141.95%

AVTX Earnings

Earnings (TTM)

-31.5M

Earnings Growth (Yr)

16.75%

Earnings Growth (Qtr)

-56.24%

Breaking Down AVTX Revenue

Last 7 days

2.7%

Last 30 days

1.5%

Last 90 days

246.6%

Trailing 12 Months

-97.9%

How does AVTX drawdown profile look like?

AVTX Financial Health

Current Ratio

1.82

Debt/Equity

1.95

Debt/Cashflow

-2.15

AVTX Investor Care

Shares Dilution (1Y)

1780.16%

Diluted EPS (TTM)

-184.8

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	14.0M	10.0M	6.0M	1.9M
2022	6.1M	3.8M	17.4M	18.1M
2021	4.4M	6.4M	6.7M	5.4M
2020	6.9M	6.9M	5.8M	6.7M
2019	7.0M	6.9M	6.8M	6.8M
2018	32.2M	36.5M	15.6M	7.0M
2017	1.5M	10.3M	19.1M	27.8M
2016	0	0	0	1.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Avalo Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 27, 2023	armistice capital, llc	sold	-486,888	0.5194	-937,404	-
Jun 26, 2023	caissa capital management ltd.	bought	-113,026	0.62	-182,300	-
Jun 26, 2023	armistice capital, llc	sold	-1,682,010	0.6125	-2,746,140	-
Jun 26, 2023	caissa capital management ltd.	bought	-917,153	0.6433	-1,425,700	-
Jun 20, 2023	caissa capital management ltd.	bought	8,288	4.1444	2,000	-
Jun 16, 2023	caissa capital management ltd.	bought	11,714	3.9048	3,000	-
Jun 15, 2023	caissa capital management ltd.	bought	11,640	3.6837	3,160	-
Jun 14, 2023	caissa capital management ltd.	bought	20,874	3.479	6,000	-
Jun 13, 2023	caissa capital management ltd.	bought	33,439	3.8216	8,750	-
Jun 12, 2023	caissa capital management ltd.	bought	9,316	4.3352	2,149	-

Which funds bought or sold AVTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	new	-	87.00	87.00	-%
Apr 26, 2024	First Horizon Advisors, Inc.	sold off	-100	-9.00	-	-%
Apr 10, 2024	Banque Cantonale Vaudoise	new	-	2,000	2,000	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-11,082	-	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-22,000	-	-%
Feb 15, 2024	JANE STREET GROUP, LLC	sold off	-100	-3,317	-	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	sold off	-100	-21.00	-	-%
Feb 14, 2024	Royal Bank of Canada	new	-	1,000	1,000	-%
Feb 14, 2024	Royal Bank of Canada	sold off	-100	-	-	-%

Are Funds Buying or Selling AVTX?

Are funds buying AVTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AVTX

No. of Funds

Unveiling Avalo Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 23, 2024	emerald bioventures, llc	5.6%	58,346	SC 13G
Apr 05, 2024	deep track capital, lp	9.99%	114,775	SC 13G
Feb 14, 2024	venrock healthcare capital partners iii, l.p.	0.0%	0	SC 13G/A
Feb 14, 2024	point72 asset management, l.p.	0.3%	2,500	SC 13G/A
Feb 14, 2024	nantahala capital management, llc	4.9%	42,100	SC 13G/A
Feb 14, 2024	great point partners llc	0.26%	2,085	SC 13G/A
Jun 29, 2023	caissa capital management ltd.	0%	0	SC 13G/A
Jun 28, 2023	armistice capital, llc	4.7%	588,850	SC 13D/A
Apr 19, 2023	caissa capital management ltd.	9.81%	1,292,700	SC 13G/A
Feb 17, 2023	venrock healthcare capital partners iii, l.p.	9.99%	1,352,285	SC 13G

Recent SEC filings of Avalo Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	SC 13G	Major Ownership Report
Apr 09, 2024	D	D
Apr 05, 2024	SC 13G	Major Ownership Report
Apr 03, 2024	3	Insider Trading
Apr 03, 2024	3	Insider Trading
Apr 03, 2024	3	Insider Trading
Mar 29, 2024	8-K	Current Report
Mar 29, 2024	10-K	Annual Report
Mar 28, 2024	DEFA14A	DEFA14A
Mar 28, 2024	8-K	Current Report

Peers (Alternatives to Avalo Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Avalo Therapeutics, Inc. News

Latest updates

Avalo Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	141.9%	571,000	236,000	643,000	769,500	896,000	14,949,000	1,033,000	1,173,000	219,500	1,350,000	3,355,000	473,000	1,496,500	1,111,000	1,338,000	2,754,000	580,808	2,201,232	1,391,942	2,576,369	3,325,578
Costs and Expenses	106.4%	8,229,000	3,986,000	7,793,000	9,267,000	9,750,500	10,854,000	12,861,000	22,026,000	18,182,000	17,813,000	20,484,000	31,053,000	17,835,000	14,388,000	13,153,000	34,167,000	6,303,643	5,062,795	3,940,011	7,581,311	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,328,632	10,425,250	12,434,215	10,477,384
S&GA Expenses	7.4%	2,675,500	2,490,000	2,427,000	2,708,000	2,959,000	3,284,000	2,784,000	11,684,000	8,437,000	5,926,000	7,404,000	435,000	549,000	462,000	653,000	677,000	547,701	214,207	325,861	396,276	-5,338,146
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,401,189	1,093,160
EBITDA Margin	-199.8%	-15.31	-5.11	-2.19	-1.90	-2.13	-2.64	-17.42	-13.74	-13.97	-11.38	-11.28	-18.01	-7.73	-	-	-	-	-	-	-	-
Interest Expenses	-100.0%	-	486,000	735,000	704,000	675,000	599,000	826,000	831,000	789,000	796,000	-	-	-	-	-	-	262,500	262,500	262,500	262,500	262,500
Income Taxes	-212.5%	-9,000	8,000	7,000	8,000	8,500	5,000	5,000	9,000	-11,500	-	-200,000	11,000	-141,000	3,000	-500,000	-2,200,000	-30,504	121,640	100,000	100,000	-141,542
Earnings Before Taxes	-56.6%	-8,177,000	-5,220,000	-8,186,000	-9,947,000	-9,803,500	3,197,000	-12,982,000	-22,042,000	-	-17,463,000	-17,373,000	-30,563,000	-	-13,258,000	-13,280,000	-24,312,000	-	-2,808,852	-2,490,747	-5,031,702	-
EBT Margin	-194.4%	-16.39	-5.57	-2.48	-2.11	-2.31	-2.84	-18.50	-14.34	-14.57	-11.78	-11.57	-18.43	-8.01	-	-	-	-	-	-	-	-
Net Income	-56.2%	-8,168,000	-5,228,000	-8,193,000	-9,955,000	-9,812,000	3,192,000	-12,987,000	-22,051,000	-19,196,000	-17,395,000	-17,105,000	-30,680,000	-15,643,000	-13,459,000	-13,281,000	-21,117,000	1,621,054	-4,016,454	-6,223,099	-7,454,048	-5,558,913
Net Income Margin	-194.2%	-16.40	-5.57	-2.48	-2.11	-2.31	-2.94	-18.97	-12.42	-15.63	-12.11	-11.95	-16.54	-9.48	-	-	-	-	-	-	-	-
Free Cashflow	59.4%	-2,766,000	-6,814,000	-11,048,000	-10,052,000	-3,940,000	5,687,000	-12,526,000	-16,067,000	-17,110,000	-16,371,000	-19,187,000	-18,337,000	-14,375,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-28.3%	21.00	29.00	24.00	36.00	33.00	37.00	32.00	62.00	80.00	95.00	64.00	63.00	44.00	59.00	69.00	44.00	36.00	57.00	60.00	75.00	70.00
Current Assets	-33.7%	8.00	13.00	8.00	19.00	16.00	19.00	15.00	44.00	62.00	77.00	47.00	46.00	26.00	41.00	50.00	25.00	18.00	13.00	14.00	27.00	22.00
Cash Equivalents	-27.2%	7.00	10.00	6.00	17.00	13.00	17.00	11.00	38.00	55.00	72.00	40.00	38.00	19.00	33.00	45.00	6.00	4.00	5.00	9.00	16.00	11.00
Inventory	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	0.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.00	2.00	1.00	1.00	1.00	2.00	1.00	1.00
Goodwill	-27.1%	11.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	16.00	16.00	16.00	14.00
Liabilities	-6.1%	14.00	15.00	31.00	43.00	44.00	39.00	38.00	56.00	57.00	55.00	42.00	30.00	19.00	21.00	19.00	19.00	15.00	39.00	42.00	52.00	49.00
Current Liabilities	-23.1%	5.00	6.00	22.00	23.00	22.00	18.00	15.00	18.00	20.00	19.00	22.00	26.00	15.00	17.00	15.00	15.00	12.00	17.00	19.00	28.00	26.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.00	14.00	14.00	14.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	1.00	1.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.00	14.00	14.00	14.00
Shareholder's Equity	-50.3%	7.00	15.00	-	-	-10.91	-	-	6.00	23.00	40.00	22.00	33.00	25.00	39.00	51.00	26.00	21.00	18.00	18.00	23.00	21.00
Retained Earnings	-2.5%	-335	-326	-321	-313	-303	-294	-297	-284	-262	-243	-225	-208	-177	-162	-148	-135	-114	-115	-111	-105	-98.22
Additional Paid-In Capital	0.3%	342	341	315	307	293	292	291	290	285	283	247	242	202	201	199	161	135	134	130	129	119
Shares Outstanding	0.0%	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	5.00	-	-	-	32.00	-	-	-	184	-	-	-	112	-	-	-	81.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	59.4%	-2,766	-6,814	-11,048	-10,052	-3,940	5,726	-12,470	-16,067	-17,099	-16,290	-19,187	-18,316	-14,375	-11,870	-8,555	-5,739	-1,680	-7,615	-6,717	-3,121	-1,975
Share Based Compensation	-18.6%	776	953	893	855	843	731	668	5,312	1,892	1,758	3,074	1,448	1,437	1,447	2,786	1,116	590	819	527	597	635
Cashflow From Investing	-	-	-	-	-133	-	-39.00	-56.00	-	-11.00	-81.00	-	-21.00	-391	-63.00	12,837	-1,251	-180	-5.08	-90.96	-165	-499
Cashflow From Financing	-100.0%	1.00	10,695	598	13,748	82.00	-	-14,781	-	76.00	47,643	21,218	37,825	200	1.00	35,485	9,098	136	3,510	97.00	8,817	6,167
Buy Backs	-	-	-	3,640	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AVTX Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Revenues:

Total revenues, net

$ 1,924

$ 18,051

Operating expenses:

Cost of product sales

1,284

3,434

Research and development

13,784

31,308

Selling, general and administrative

10,300

20,711

Goodwill impairment

3,907

Amortization expense

Total operating expenses

29,275

55,491

Operating income (loss)

(27,351)

(37,440)

Other expense:

Interest expense, net

(3,417)

(4,170)

Change in fair value of derivative liability

(720)

Other expense, net

(42)

(20)

Total other expense, net

(4,179)

(4,190)

Loss before income taxes

(31,530)

(41,630)

Income tax expense

Net loss

$ (31,544)

$ (41,658)

Net loss per share of common stock, basic (in dollars per share)

^[1]

$ (114)

$ (1,063)

Net loss per share of common stock, diluted (in dollars per share)

^[1]

$ (114)

$ (1,063)

Product revenue, net

Revenues:

Total revenues, net

$ 1,408

$ 3,364

License and other revenue

Revenues:

Total revenues, net

$ 516

$ 14,687

[1]	Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-240 reverse stock split effected on December 28, 2023. See Note 1 for details.

AVTX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)
$ in Thousands

Dec. 31, 2023

Dec. 31, 2022

Current assets:

Cash and cash equivalents

$ 7,415

$ 13,172

Other receivables

136

1,919

Inventory, net

Prepaid expenses and other current assets

843

1,290

Restricted cash, current portion

Total current assets

8,395

16,416

Property and equipment, net

1,965

2,411

Goodwill

10,502

14,409

Restricted cash, net of current portion

131

Total assets

20,993

33,367

Current liabilities:

Accounts payable

446

2,882

Deferred revenue

Accrued expenses and other current liabilities

4,172

13,214

Notes payable, current

5,930

Total current liabilities

4,618

22,114

Notes payable, non-current

13,486

Royalty obligation

2,000

Deferred tax liability, net

155

141

Derivative liability

5,550

4,830

Other long-term liabilities

1,366

1,711

Total liabilities

13,689

44,282

Stockholders’ equity (deficit) :

Common stock—$0.001 par value; 200,000,000 shares authorized at December 31, 2023 and 2022; 801,746 and 39,295 shares issued and outstanding at December 31, 2023 and 2022, respectively

^[1]

Additional paid-in capital

^[1]

342,437

292,909

Accumulated deficit

(335,134)

(303,824)

Total stockholders’ equity (deficit)

7,304

(10,915)

Total liabilities and stockholders’ equity (deficit)

$ 20,993

$ 33,367

[1]	Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-240 reverse stock split effected on December 28, 2023. See Note 1 for details.

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

CEO	Dr. Garry A. Neil M.D.
WEBSITE	avalotx.com
INDUSTRY	Biotechnology
EMPLOYEES	20

Avalo Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Avalo Therapeutics, Inc.? What does AVTX stand for in stocks?

AVTX is the stock ticker symbol of Avalo Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Avalo Therapeutics, Inc. (AVTX)?

As of Thu May 02 2024, market cap of Avalo Therapeutics, Inc. is 15.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVTX stock?

You can check AVTX's fair value in chart for subscribers.

What is the fair value of AVTX stock?

You can check AVTX's fair value in chart for subscribers. The fair value of Avalo Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Avalo Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AVTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Avalo Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether AVTX is over valued or under valued. Whether Avalo Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Avalo Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVTX.

What is Avalo Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, AVTX's PE ratio (Price to Earnings) is -0.5 and Price to Sales (PS) ratio is 8.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVTX PE ratio will change depending on the future growth rate expectations of investors.